45866 Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices 

analogues of monamine transporters to 

treat substance use disorders and sleep 

disorders within the scope of the 

Licensed Patent Rights’’. Comments/ 

Objections were not received in 

response to the NOITG. After 

consideration, an exclusive license was 

granted to EncepHeal with a Licensed 

Field of Use of: ‘‘Use of analogues of 

monamine transporters to treat 

substance use disorders within the 

scope of the Licensed Patent Rights’’. 

This Notice advises the public that the 

NIH intends to modify the Licensed 

Field of Use originally granted to 

EncepHeal. Specifically, the National 

Institute on Drug Abuse is proposing to 

modify the Licensed Field of Use to be 

‘‘use of a lead compound to treat one or 

more of the following: Substance use 

disorders, cognitive deficits, sleep 

disorders, attention deficit hyperactivity 

disorder and depressive disorders. The 

modification to the Licensed Field of 

Use in the Exclusive Patent License 

requires EncepHeal to select a lead 

compound for each of the disorders 

listed in the Field of Use and that upon 

selection of a lead compound for a 

disorder, the other compounds of the 

technology will become available for 

licensing to other companies. 

The technology is directed to novel 

analogues of modafinil. Modafinil 

(marketed as Provisil in United States) 

is approved by FDA to treat narcolepsy 

and other sleep disorders. Modafinil has 

been studied as a possible treatment for 

cognitive dysfunction in disorders such 

as attention-deficit hyperactivity 

disorders (ADHD) as well as cocaine 

and methamphetamine addiction. 

However, it has a relatively low affinity 

for dopamine transporter (DAT) and is 

water-insoluble, thus requiring large 

doses to achieve pharmacological 

effects. Early studies indicated that 

modafinil reduced cocaine intake more 

effectively than placebo; however, 

subsequent larger studies reported only 

modest effectiveness in reducing 

cocaine intake. The library of 

compounds in the technology are 

analogs of modafinil and are designed to 

have higher affinities for DAT and 

improved water solubility. The National 

Institute on Drug Abuse has conducted 

preliminary experiments on many of the 

compounds and has identified several 

compounds that have higher affinities 

than modafinil for the DAT and lower 

affinity than modafinil for several other 

off target receptors. Preliminary studies 

at the National Institute on Drug Abuse 

indicate that some of the compounds 

have in vivo activity in rodents to 

inhibit cocaine taking behavior and are 

not selectively self-administered 

themselves (i.e. have low abuse 

liability). 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404 

and incorporates by reference: 

‘‘Prospective Grant of Exclusive Option 

License: Potent and Selective Analogues 

of: Monamine Transporters; Methods of 

Making; and Uses Thereof’’ FR 80:245 

(December 22, 2015), pp. 79595–79596. 

The prospective modification of the 

Exclusive Patent License will be royalty 

bearing and may be granted unless 

within fifteen (15) days from date of this 

published notice, the National Institute 

on Drug Abuse receives written 

evidence and argument that establishes 

that the grant of modification to the 

license would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR Part 404. 

Complete applications for a license in 

the field of use filed in response to this 

notice will be treated as objections to 

the grant of the contemplated 

modification to Exclusive Patent 

License. Comments and objections 

submitted to this notice will not be 

made available for public inspection 

and, to the extent permitted by law, will 

not be released under the Freedom of 

Information Act, 5 U.S.C. 552. 

Dated: September 22, 2107. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2017–21048 Filed 9–29–17; 8:45 am] 

BILLING CODE 4040–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Program Project Grant P01. 

Date: October 23, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 

(Teleconference Meeting). 

Contact Person: Ana Olariu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, ana.olariu@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders A. 

Date: October 23–24, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Avenue NW., Washington, DC 20037. 

Contact Person: Natalia Strunnikova, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, NINDS/NIH/DHHS, 

Neuroscience Center, 6001 Executive Blvd., 

Suite 3204, MSC 9529, Bethesda, MD 20892– 

9529, (301) 402–0288, natalia.strunnikova@

nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; K99/R00 Review. 

Date: October 23, 2017. 

Time: 11:30 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Crystal City, 2399 Jefferson 

Davis Highway, Arlington, VA 22202. 

Contact Person: Elizabeth A. Webber, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, NINDS/NIH/DHHS, 

Neuroscience Center, 6001 Executive Blvd., 

Suite 3204, MSC 9529, Bethesda, MD 20892– 

9529, (301) 496–1917, webbere@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders B. 

Date: October 26–27, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Admiral Fell Inn, 888 South 

Broadway, Baltimore, MD 21231. 

Contact Person: Birgit Neuhuber, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, neuhuber@ninds.nih.gov@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Ruth L. Kirschstein National 

Research Service Award (NRSA) Institutional 

Research Training Grant (T32) Program. 

Date: October 30–31, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco, 700 F Street NW., 

Washington, DC 20001. 

Contact Person: William Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 189 / Monday, October 2, 2017 / Notices 45867 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–0660, benzingw@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; BPN Review Meeting. 

Date: November 3, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Glover Park Hotel, 2505 Wisconsin 

Avenue NW., Washington, DC 20007. 

Contact Person: Joel Saydoff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, joel.saydoff@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Initial 

Review Group; Neurological Sciences and 

Disorders K. 

Date: November 6, 2017. 

Time: 2:00 a.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

435–6033, rajarams@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: September 26, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20991 Filed 9–29–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Arthritis and 

Musculoskeletal and Skin Diseases Initial 

Review Group; Arthritis and Musculoskeletal 

and Skin Diseases Clinical Trials Review 

Committee. 

Date: October 24, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott, 5701 

Marinelli Road, Rockville, MD 20852. 

Contact Person: Kathy Salaita, SCD, Chief, 

Scientific Review Branch, National Institute 

of Arthritis and Musculoskeletal and Skin 

Diseases, DHHS/National Institutes of Health, 

6701 Democracy Blvd., Rm. 818, Bethesda, 

MD 20892, 301–594–5033 (office), 301–402– 

2406 (fax), Kathy.Salaita@nih.gov. 

Name of Committee: National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases Special Emphasis Panel; AMSC 

Conflict Review Meeting. 

Date: October 26, 2017. 

Time: 11:00 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Arthritis and 

Musculoskeletal and Skin Diseases, 6701 

Democracy Boulevard, Suite 816, Bethesda, 

MD 20892 (Teleconference). 

Contact Person: Nakia C. Brown, Ph.D., 

Scientific Review Officer, 6701 Democracy 

Boulevard, Room 816, Bethesda, MD 20892, 

301–827–4905, brownnac@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: September 26, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20989 Filed 9–29–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Muscular Dystrophy 

Coordinating Committee. 

The meeting will be open to the 

public and accessible by teleconference 

and live WebEx. Members of the public 

who wish to participate using WebEx 

should contact the Contact Person listed 

on this notice for the WebEx details. 

Individuals who plan to participate and 

need special assistance, such as 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Type of meeting: Open Meeting. 

Date: December 5, 2017. 

Time: 1:00 p.m. to 2:30 p.m. *Eastern 

Time* 

Agenda: The purpose of this meeting is to 

bring together committee members, 

representing government agencies, patient 

advocacy groups, other voluntary health 

organizations, and patients and families to 

update one another on progress relevant to 

the Action Plan for the Muscular 

Dystrophies. 

Place: National Institutes of Health, 6001 

Executive Boulevard, Rockville, MD 20852 

(Telephone Conference Call). 

Call-In Number: 1–650–479–3208. 

Public Access Code: 622 734 375. 

Contact Person: Glen Nuckolls, Ph.D., 

Program Director, National Institute of 

Neurological Disorders and Stroke, NIH, 6001 

Executive Boulevard, Room 2203, Rockville, 

MD 20892, Phone: (301) 496–5876, Email: 

nuckollg@ninds.nih.gov. 

Prior to the meeting, an agenda will be 

posted to the MDCC Web site: 

www.mdcc.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: September 26, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–20990 Filed 9–29–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 


sradovich on DSK3GMQ082PROD with NOTICES